Eli Lilly Tops Quarterly Estimates and Raises Outlook as Zepbound and Mounjaro Sales Surge

The Quick Take

• Eli Lilly easily beat quarterly earnings estimates and raised its full-year guidance, driven by surging sales of GLP-1 drugs Zepbound and Mounjaro.
• Mounjaro (tirzepatide for diabetes) and Zepbound (tirzepatide for obesity) continue to capture market share from Novo Nordisk's Ozempic and Wegovy in the fast-growing GLP-1 category.
• The raised guidance signals management confidence that supply constraints in the GLP-1 market are easing as Lilly accelerates manufacturing capacity expansion.

Eli Lilly delivered another decisive quarterly beat, with Zepbound and Mounjaro — its dual-indication tirzepatide formulations for obesity and type 2 diabetes respectively — driving revenue well above consensus expectations. Management accompanied the results with a raised full-year outlook, signaling that the GLP-1 drug category's growth trajectory remains robust and that earlier supply constraints which had limited revenue realization are now easing as manufacturing investments come online. Lilly's tirzepatide franchise has demonstrated superior clinical weight-loss outcomes versus Novo Nordisk's semaglutide, providing a compelling commercial narrative for market share gains.

The earnings performance creates significant ripple effects across the healthcare and adjacent sectors. Novo Nordisk, Lilly's primary GLP-1 competitor, faces intensified pressure on its Ozempic/Wegovy franchise as Lilly's supply normalization closes the availability gap. Pharmacy benefit managers and health insurers who had been selectively restricting GLP-1 coverage face a new pricing negotiation dynamic as commercial supply increases. Medical device companies in the cardiovascular and bariatric surgery space — particularly makers of continuous glucose monitors and insulin delivery systems — face long-term volume risk as GLP-1 adoption reduces the progression to advanced diabetes complications.

The forward earnings trajectory for Lilly hinges on the pace of manufacturing capacity additions, where the company has committed billions in global facility investments. Investors should watch Lilly's Q3 guidance revision and any data from the SURPASS or SURMOUNT trial extensions that could expand tirzepatide indications beyond current approvals. The macro risk is US government pricing intervention — the IRA's Medicare drug price negotiation framework and potential direct price caps on GLP-1 drugs represent the single largest regulatory uncertainty for Lilly's revenue trajectory over the next three years.

Synthesized from 1 source.